Want to see BCDA full AI Analyst Report?
BCDA Stock Chart & Stats
$0.85
-$0.04(-4.92%)
At close: 4:00 PM EDT
$0.85
-$0.04(-4.92%)
Day’s Range― - ―
52-Week Range$0.75 - $2.29
Previous Close$0.82
Volume275.31K
Average Volume (3M)831.61K
Market Cap
$15.29M
Enterprise Value$11.17
Total Cash (Recent Filing)$4.12M
Total Debt (Recent Filing)$293.00K
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Nov 11, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.76
Shares Outstanding15,138,782
10 Day Avg. Volume300,873
30 Day Avg. Volume831,610
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)9.31
Price to Sales (P/S)0.00
P/FCF Ratio-1.12
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$25.00Price Target Upside2841.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.68
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Japan Regulatory PathwayPMDA support establishes a defined route toward Japanese commercialization and validates prior trial outcomes. The targeted population of about 20,000 patients provides a meaningful initial market if remaining documentation and approval requirements are completed.
U.S. Regulatory ProgressFDA alignment may reduce the need for additional pivotal evidence and improve the path to U.S. clearance. A single confirmatory trial could make development more capital-efficient, although outcome-measure discussions remain important.
Delivery Platform StrengthClinical experience and regulatory feedback support HELIX as a differentiated delivery platform for BioCardia’s therapies and potential partners. Its established use may strengthen development credibility across cardiovascular and biotherapeutic applications.
Bears Say
No Commercial RevenueThe absence of meaningful revenue leaves BioCardia dependent on successful clinical development, partnerships, or future financing. Persistent losses also limit internal funding capacity and make long-term profitability highly dependent on regulatory and commercial execution.
Persistent Cash BurnSustained operating and free-cash-flow deficits require BioCardia to draw on cash reserves or raise capital to continue trials and submissions. Even with runway into 2027, additional funding may be needed to accelerate programs, creating dilution and execution risk.
Trial Execution And Regulatory RiskSlow, resource-dependent enrollment can delay confirmatory evidence and commercialization, while added documentation and endpoint work may extend regulatory timelines. These constraints increase development costs and could postpone the company’s ability to generate recurring revenue.
BioCardia News
BCDA FAQ
What was Biocardia’s price range in the past 12 months?
Biocardia lowest stock price was $0.75 and its highest was $2.29 in the past 12 months.
What is Biocardia’s market cap?
Biocardia’s market cap is $15.29M.
When is Biocardia’s upcoming earnings report date?
Biocardia’s upcoming earnings report date is Nov 11, 2026 which is in 79 days.
How were Biocardia’s earnings last quarter?
Biocardia released its earnings results on Aug 12, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.18 by $0.05.
Is Biocardia overvalued?
According to Wall Street analysts Biocardia’s price is currently Undervalued.
Does Biocardia pay dividends?
Biocardia does not currently pay dividends.
What is Biocardia’s EPS estimate?
Biocardia’s EPS estimate is -0.13.
How many shares outstanding does Biocardia have?
Biocardia has 15,138,782 shares outstanding.
What happened to Biocardia’s price movement after its last earnings report?
Biocardia reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.18. Following the earnings report the stock price went up 5.455%.
Which hedge fund is a major shareholder of Biocardia?
Currently, no hedge funds are holding shares in BCDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biocardia
BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions. The company is further exploring a specific allogeneic cell therapeutic platform. This investigational treatment, derived from culture-expanded mesenchymal cells sourced from bone marrow, is currently undergoing Phase I/II trials for patients suffering from ischemic systolic heart failure. Beyond its therapeutic candidates, BioCardia also provides innovative delivery solutions. These include the Helix biotherapeutic delivery system, engineered to precisely administer treatments directly into the heart muscle via an internal penetrating helical needle, and a line of Morph deflectable guides and sheaths. BioCardia maintains its headquarters in Sunnyvale, California.
BCDA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized meaningful regulatory progress across Japan (PMDA) and the U.S. (FDA) and favorable feedback for the HELIX catheter, supported by substantial clinical experience (~500 Helix patients, >20x procedural experience vs peers). Financially, the company improved expense control and narrowed net losses, and raised ~$4.9M, leaving cash into 2027. Key challenges include additional PMDA documentation requests, relatively slow enrollment in the U.S. confirmatory trial that is resource-constrained, tight near-term financing needs to accelerate enrollment, and some regulatory process uncertainties (FDA minutes delay, endpoint discussions, reimbursement timing). On balance, positives (regulatory momentum, commercialization pathway in Japan, improved financial trends) materially outweigh the operational and cash runway challenges, though execution risk remains.View all BCDA earnings summariesBCDA Stock 12 Month Forecast
Average Price Target
$25.00
▲(2841.18% Upside)
Technical Analysis
Pluri
―
Celularity
―
Revelation Biosciences
―
SeaStar Medical Holding
―
Cardio Diagnostics Holdings
―
Ownership Overview
14.44% Insiders
1.24% Mutual Funds
2.92% Other Institutional Investors
80.58% Public Companies and
Individual Investors